Could a gut bacteria boost cancer immunotherapy? new trial launches

NCT ID NCT07128680

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the supplement. The goal is to see if the bacteria can improve the immune response against the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab, ipilimumab, and EXL01 (a live bacterial supplement)
What this could lead to
If it works, this could point toward a way to boost the immune system's attack on kidney cancer by adding a gut bacteria supplement to standard immunotherapy.
What could go wrong
This is a very early (Phase 1) and small (33 people) trial, so it is mainly checking safety. The bacteria supplement may not help, and side effects from the immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • City of Hope Medical Center

    RECRUITING

    Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.